- Home
- OM
as of 02-09-2026 4:00pm EST
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Upcoming Earnings Alert:
Get ready for potential market movements as Outset Medical Inc. (OM) prepares to release earnings report on 11 Feb 2026.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 91.5M | IPO Year: | 2020 |
| Target Price: | $14.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.10 - $21.98 | Next Earning Date: | 02-11-2026 |
| Revenue: | $120,069,000 | Revenue Growth: | 4.65% |
| Revenue Growth (this year): | 6.23% | Revenue Growth (next year): | 8.87% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -53912000.0 | FCF Growth: | N/A |
AI-Powered OM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Outset Medical Inc. (OM)
Chair and CEO
Avg Cost/Share
$5.05
Shares
2,120
Total Value
$10,706.00
Owned After
105,703
SEC Form 4
General Counsel
Avg Cost/Share
$5.01
Shares
1,180
Total Value
$5,911.80
Owned After
35,777
SEC Form 4
Chair and CEO
Avg Cost/Share
$5.12
Shares
11,794
Total Value
$60,385.28
Owned After
105,703
SEC Form 4
General Counsel
Avg Cost/Share
$5.12
Shares
9,314
Total Value
$47,687.68
Owned After
35,777
SEC Form 4
Chair and CEO
Avg Cost/Share
$4.27
Shares
1,795
Total Value
$7,664.65
Owned After
105,703
SEC Form 4
General Counsel
Avg Cost/Share
$4.27
Shares
224
Total Value
$956.48
Owned After
35,777
SEC Form 4
Director
Avg Cost/Share
$4.37
Shares
1,548
Total Value
$6,764.76
Owned After
10,650
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nash Marc | OM | EVP Operations R&D & Service | Jan 21, 2026 | Sell | $4.98 | 980 | $4,880.40 | 41,805 | |
| Trigg Leslie | OM | Chair and CEO | Jan 21, 2026 | Sell | $5.05 | 2,120 | $10,706.00 | 105,703 | |
| Brottem John L. | OM | General Counsel | Jan 21, 2026 | Sell | $5.01 | 1,180 | $5,911.80 | 35,777 | |
| Nash Marc | OM | EVP Operations R&D & Service | Jan 20, 2026 | Sell | $5.12 | 5,375 | $27,520.00 | 41,805 | |
| Trigg Leslie | OM | Chair and CEO | Jan 20, 2026 | Sell | $5.12 | 11,794 | $60,385.28 | 105,703 | |
| Brottem John L. | OM | General Counsel | Jan 20, 2026 | Sell | $5.12 | 9,314 | $47,687.68 | 35,777 | |
| Nash Marc | OM | EVP Operations R&D & Service | Jan 7, 2026 | Sell | $4.27 | 108 | $461.16 | 41,805 | |
| Trigg Leslie | OM | Chair and CEO | Jan 7, 2026 | Sell | $4.27 | 1,795 | $7,664.65 | 105,703 | |
| Brottem John L. | OM | General Counsel | Jan 7, 2026 | Sell | $4.27 | 224 | $956.48 | 35,777 | |
| Drexler Karen | OM | Director | Dec 1, 2025 | Sell | $4.37 | 1,548 | $6,764.76 | 10,650 |
Compare OM vs Leading Stocks
See how OM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OM Outset Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.